Get started
Author

Zhicong He

Observed name: Z. He
ORCID: 0009-0009-4505-7418
Observed ORCID: 0009-0009-4505-7418
OpenAlex ID: A5031682845
Autologous Endothelial Progenitor Cells Transplantation for Acute Ischemic Stroke: A 4-Year Follow-Up Study
2018 · Jie Fang, Yang Guo, et al. · Stem Cells Translational Medicine · 109
PDF
Phoenixin-14 enhances memory and mitigates memory impairment induced by Aβ1-42 and scopolamine in mice
2015 · J.H. Jiang, Z. He, et al. · Brain Research · 55
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2023 · Sikander Ailawadhi, Zi Chen, et al. · Clinical Cancer Research · 42
PDF
First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).
2021 · Sikander Ailawadhi, Asher Alban Akmal Chanan-Khan, et al. · Journal of Clinical Oncology · 24
Trial in progress: A multicenter phase Ib/II study of pelcitoclax (APG-1252) in combination with paclitaxel in patients with relapsed/refractory small-cell lung cancer (R/R SCLC).
2021 · Angel Qin, Gregory Peter Kalemkerian, et al. · Journal of Clinical Oncology · 5
Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2025 · Sikander Ailawadhi, Zi Chen, et al.
PDF
Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2025 · Sikander Ailawadhi, Zi Chen, et al.
Table S2 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2025 · Sikander Ailawadhi, Zi Chen, et al.
PDF
Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2024 · Sikander Ailawadhi, Zi Chen, et al.
Table S2 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2024 · Sikander Ailawadhi, Zi Chen, et al.
Data from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2024 · Sikander Ailawadhi, Zi Chen, et al.
Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2024 · Sikander Ailawadhi, Zi Chen, et al.
Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2024 · Sikander Ailawadhi, Zi Chen, et al.
Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2024 · Sikander Ailawadhi, Zi Chen, et al.
Table S2 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2024 · Sikander Ailawadhi, Zi Chen, et al.
Data from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2023 · Sikander Ailawadhi, Zi Chen, et al.
Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2023 · Sikander Ailawadhi, Zi Chen, et al.
Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2023 · Sikander Ailawadhi, Zi Chen, et al.
PDF
Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2023 · Sikander Ailawadhi, Zi Chen, et al.
PDF
Table S2 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2023 · Sikander Ailawadhi, Zi Chen, et al.
Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2023 · Sikander Ailawadhi, Zi Chen, et al.
Table S2 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2023 · Sikander Ailawadhi, Zi Chen, et al.
PDF
Data from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2023 · Sikander Ailawadhi, Zi Chen, et al.
Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2023 · Sikander Ailawadhi, Zi Chen, et al.
PDF
Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2023 · Sikander Ailawadhi, Zi Chen, et al.
Works count: 33
Citation count: 235
H-index: 5
I10-index: 4
Year
Topic
Type